Brazilian Journal of Anesthesiology
https://bjan-sba.org/article/doi/10.1590/S0034-70942010000400007
Brazilian Journal of Anesthesiology
Scientific Article

Avaliação do custo do medicamento para tratamento ambulatorial de pacientes com dor crônica

Evaluating the cost of drugs used in the outpatient treatment of chronic pain

Roberto Vlainich; Paola Zucchi; Adriana Machado Issy; Rioko Kimiko Sakata

Downloads: 1
Views: 921

Resumo

JUSTIFICATIVA E OBJETIVOS: A dor crônica é muito prevalente e o custo do tratamento pode ter impacto relevante sobre as pessoas e a sociedade. O objetivo deste estudo foi avaliar os custos mensais médios dos medicamentos para tratamento ambulatorial da dor crônica. MÉTODO: Neste estudo, analisou-se o custo de medicamentos empregados por 233 pacientes com dor crônica (117 com dor nociceptiva, 59 com dor neuropática e 57 com dor mista) e atendidos no Centro Alfa da UNIFESP, entre janeiro de 2004 e janeiro de 2008. RESULTADOS: A média de custos geral foi de R$127,74 (custo mínimo de R$5,00 e máximo de R$780,00). CONCLUSÕES: O estudo revelou que os custos de medicamentos não diferem de forma significativa, levando-se em conta o tipo de dor envolvida.

Palavras-chave

DROGAS

Abstract

BACKGROUND AND OBJECTIVES: Chronic pain is very prevalent and the cost of its treatment can cause a relevant impact on people and society. The objective of this study was to evaluate the monthly cost of drugs used in the outpatient treatment of chronic pain. METHODS: In the present study the cost of the drugs used by 233 patients with chronic pain (117 with nociceptive pain, 59 with neuropathic pain, and 57 with mixed pain) followed at the Alpha Center of UNIFESP between January 2004 and January 2008 was evaluated. RESULTS: The mean general cost was R$ 127.74 (from R$ 5.00 to R$ 780.00). CONCLUSIONS: This study showed that the cost of the drugs does not differ significantly taking into consideration the type of pain.

Keywords

DRUGS

References

Melo DO, Ribeiro E, Storpirtis S. A importância e a história dos estudos de utilização de medicamentos. RBCF Rev Bras Cienc Farm. 2006;42:475-485.

Lessard C, Contandriopoulos AP, Beaulieu MD. The role of economic evaluation in the decision-making process of family physicians: design and methods of a qualitative embedded multiple-case study. BMC Farm Pract. 2009;10.

Robertson J, Lang D, Hill S. Use of pharmacoeconomics in prescribing research: Part 1: costs-moving beyond the acquisition price for drugs. J Clin Pharm Ther. 2003;28:73-79.

Zanini AC, Farhat FCLG, Ribeiro E. Farmacoeconomia: conceitos e aspectos operacionais. RBCF Rev Bras Cienc Farm. 2001;37:225-237.

Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol. 1993;46:1417-1432.

Fitzpatrick R, Fletcher A, Gore S. Quality of life measures in health care: I: Applications and issues in assessment. BMJ. 1992;305:1074-1077.

The World Health Organization Quality of Life Assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41:1403-1409.

Shlipak MG. Análise de Decisão. Friedland Medicina Baseada em Evidências: uma Estrutura para a Prática Clínica. 2001:32-51.

Cramer JA, Spilker B. Quality of Life and Pharmacoeconomics. 1998:221-264.

Rittenhouse BE. Designing and Conducting Cost-Minimization and Cost-Effectiveness Analyses. Quality of Life and Pharmacoeconomics in Clinical Trials. 1996:741-745.

Davies L, Cossins L, Bowsher D. The cost of treatment for postherpetic neuralgia in the UK. Pharmacoeconomics. 1994;6:142-148.

Manktelow RT, Binhammer P, Tomat LR. Carpal tunnel syndrome: cross-sectional and outcome study in Ontario workers. J Hand Surg(Am). 2004;29:307-317.

Scott FT, Johnson RW, Leedham-Green M. The burden of herpes zoster: a prospective population based study. Vaccine. 2006;24:1308-1314.

Cepeda MS, Farrar JT. Economic evaluation of oral treatments for neuropathic pain. J Pain. 2006;7:119-128.

O'Connor AB. Re: sequential medication strategies for postherpetic neuralgia: a cost-effectiveness analysis. J Pain. 2007;8:674-676.

Rodríguez MJ, Díaz S, Vera-Llonch M. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin. 2007;23:2585-2596.

Smith KJ, Roberts MS. Sequential medication strategies for postherpetic neuralgia: a cost-effectiveness analysis. J Pain. 2007;8:396-404.

Beard SM, McCrink L, Le TK. Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. Curr Med Res Opin. 2008;24:385-399.

5dceb6570e88259405bf58f1 rba Articles
Links & Downloads

Braz J Anesthesiol

Share this page
Page Sections